Gland Pharma shares rose 3.89% after reporting strong Q2 FY27 results, with revenue growing 23% and net profit jumping 58% year-on-year. The stock touched a 52-week high of Rs 3,345, supported by robust CDMO growth, improved margins, new product launches and increased US regulatory approvals.
Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%
Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target